Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

Dimitrios Mavroudis; Emmanouil Saloustros; Ioannis Boukovinas; Pavlos Papakotoulas; Stylianos Kakolyris; Nikolaos Ziras; Charalampos Christophylakis; Nikolaos Kentepozidis; Georgios Fountzilas; Georgios Rigas; Ioannis Varthalitis; Konstantinos Kalbakis; Sofia Agelaki; Dora Hatzidaki; Vasilios Georgoulias

doi:10.1038/bjc.2017.158

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

British Journal of Cancer ◽

10.1038/bjc.2017.158 ◽

2017 ◽

Vol 117 (2) ◽

pp. 164-170 ◽

Cited By ~ 4

Author(s):

Dimitrios Mavroudis ◽

Emmanouil Saloustros ◽

Ioannis Boukovinas ◽

Pavlos Papakotoulas ◽

Stylianos Kakolyris ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Early Breast Cancer ◽

Research Group ◽

Interim Analysis ◽

Phase Iii ◽

Node Negative ◽

Oncology Research ◽

Phase Iii Study

Download Full-text

Abstract P1-12-02: Sequential versus concurrent administration of epirubicin and docetaxel as adjuvant chemotherapy in women with high-risk axillary lymph node negative early breast cancer. An interim analysis of a multicenter randomized study from the Hellenic oncology research group

10.1158/1538-7445.sabcs15-p1-12-02 ◽

2016 ◽

Author(s):

D Mavroudis ◽

E Saloustros ◽

I Boukovinas ◽

P Papakotoulas ◽

S Kakolyris ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Interim Analysis ◽

Randomized Study ◽

Axillary Lymph ◽

Concurrent Administration ◽

Node Negative ◽

Oncology Research

Download Full-text

Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.542 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 542-542 ◽

Cited By ~ 3

Author(s):

M. Martin ◽

A. Iluch ◽

M. Segui ◽

A. Ruiz ◽

M. Ramos ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Phase Iii ◽

Node Negative ◽

Efficacy Analysis ◽

Node Negative Breast Cancer ◽

Phase Iii Study

Download Full-text

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

10.1158/0008-5472.sabcs10-s4-2 ◽

2010 ◽

Cited By ~ 11

Author(s):

J O'Shaughnessy ◽

D Paul ◽

C Stokoe ◽

J Pippen Jr ◽

JL Blum ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)

Breast Cancer Research and Treatment ◽

10.1007/s10549-009-0468-0 ◽

2009 ◽

Vol 119 (1) ◽

pp. 95-104 ◽

Cited By ~ 29

Author(s):

Aristides Polyzos ◽

Nikolaos Malamos ◽

Ioannis Boukovinas ◽

Adamos Adamou ◽

Nikolaos Ziras ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Early Breast Cancer ◽

Research Group ◽

Randomized Study ◽

Axillary Node ◽

Node Positive ◽

Oncology Research

Download Full-text

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.500 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 500-500 ◽

Cited By ~ 4

Author(s):

J. E. Pippen ◽

D. Paul ◽

C. T. Stokoe ◽

J. L. Blum ◽

L. Krekow ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Ki 67 ◽

Phase Iii Study

Download Full-text

Phase III Randomized Comparison of Postoperative Adjuvant Chemotherapy with 2-Year Oral UFT (Uracil/Tegafur) versus Six-Cycle CMF (Cyclophosphamide/Methotrexate/5-Fluorouracil) in High-risk Node-Negative Breast Cancer Patients

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/28.1.77 ◽

1998 ◽

Vol 28 (1) ◽

pp. 77-80 ◽

Cited By ~ 10

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Phase Iii ◽

Breast Cancer Patients ◽

Postoperative Adjuvant Chemotherapy ◽

Node Negative ◽

Node Negative Breast Cancer

Download Full-text

Zoledronic Acid Prevents Bone Loss in Premenopausal Women with Early Breast Cancer Undergoing Adjuvant Chemotherapy: A Phase III Study of Korean Cancer Study Group (KCSG-BR06-01).

10.1158/0008-5472.sabcs-09-2104 ◽

2009 ◽

Author(s):

J. Ahn ◽

K. Jung ◽

S. Kim ◽

K. Lee ◽

J. Ro ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Adjuvant Chemotherapy ◽

Bone Loss ◽

Early Breast Cancer ◽

Premenopausal Women ◽

Phase Iii ◽

Study Group ◽

Cancer Study Group ◽

Phase Iii Study

Download Full-text

P272 Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC), followed by docetaxel (T) with or without capecitabine (X), in high-risk early breast cancer (EBC): efficacy results

The Breast ◽

10.1016/s0960-9776(11)70214-4 ◽

2011 ◽

Vol 20 ◽

pp. S65 ◽

Cited By ~ 1

Author(s):

J. O'Shaughnessy ◽

C. Brownstein ◽

S. Hörsch ◽

N. Scotto

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Phase Iii Study

Download Full-text

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.03.056 ◽

2021 ◽

Vol 32 ◽

pp. S37-S38

Author(s):

O. Metzger ◽

C. Lambertini ◽

I.E. Krop ◽

G. Lewis Phillips ◽

C.M. Perou ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Biomarker Analysis ◽

Phase Iii Study

Download Full-text

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)

European Journal of Cancer ◽

10.1016/j.ejca.2017.03.004 ◽

2017 ◽

Vol 79 ◽

pp. 166-175 ◽

Cited By ~ 3

Author(s):

Pierre Kerbrat ◽

Isabelle Desmoulins ◽

Lise Roca ◽

Christelle Levy ◽

Alain Lortholary ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Phase Iii ◽

Breast Cancer Patients ◽

Node Negative ◽

Multicentre Phase ◽

Optimal Duration

Download Full-text